Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19698087 | 0.85 | LMNA (0.39) | EPHX1EPHX2ALDH1A1LMNAPRMT1 | |
| SCHEMBL209163 | 0.82 | DGKA (0.44) | ALDH1A1LMNA | |
| SCHEMBL2223792 | 0.81 | DGKA (0.47) | LMNA | |
| SCHEMBL4812972 | 0.81 | DGKA (0.47) | LMNA | |
| SCHEMBL18960980 | 0.81 | DGKA (0.47) | LMNA | |
| SCHEMBL19067107 | 0.81 | DGKA (0.47) | LMNA | |
| SCHEMBL28168374 | 0.80 | ALDH1A1 (0.42) | ALDH1A1LMNA | |
| SCHEMBL13356960 | 0.78 | PTGS1 (0.44) | ALDH1A1LMNA | |
| SCHEMBL714989 | 0.77 | ALDH1A1 (0.44) | ALDH1A1LMNA | |
| SCHEMBL28390950 | 0.77 | ALDH1A1 (0.38) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | EPHX1 4394/4885EPHX2 3369/4885ALDH1A1 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.